More special care is needed when using the Watchman access systems used to deliver transcatheter left atrial appendage (LAA) closure devices due to a risk for air embolisms, according to an FDA alert.

Credit: Patrick J. Lynch, medical illustrator; C. Carl Jaffe, MD, cardiologist. Adjunctive left atrial appendage (LAA) ligation failed to increase the efficacy of catheter pulmonary vein isolation ...

In patients with persistent atrial fibrillation (AF) undergoing initial catheter ablation, the addition of left atrial appendage (LAA) ligation with the Lariat system (AtriCure) did not improve ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of patency and device-related thrombus were ...

In China, left atrial appendage (LAA) occlusion using the first-generation Watchman 2.5 device (Boston Scientific) is being performed with high procedural success plus low rates of periprocedural ...

Boston Scientific Corp. and Abbott Laboratories continue to parry over clinical trials comparing the latter’s Amplatzer Amulet with Boston Scientific’s Watchman in sealing the heart’s left atrial ...

AFib is a common heart rhythm disorder consisting of rapid and irregular heartbeats, which can lead to the formation of blood clots in the heart. These clots develop in a small pouch called the left ...

ABBOTT PARK, Ill., Aug. 30, 2021 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking data from the Amulet™ LAA Occluder IDE trial, a multi-center, head-to-head study comparing the company ...